What are the AUA guidelines on the use of combination therapy for the treatment of benign prostatic hyperplasia (BPH)?

Updated: Feb 19, 2021
  • Author: Levi A Deters, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

American Urological Association (AUA) guidelines advise that combination therapy with an alpha-blocker and a 5-alpha-reductase inhibitor can be appropriate and effective for patients with lower urinary tract symtpoms (LUTS) who have enlarged prostates. [1] The alpha-1-receptor blocker provides rapid relief, while the 5-alpha-reductase inhibitor targets the underlying disease process. [13, 24]  A fixed-dose combination capsule of tamsulosin 0.4 mg and dutasteride 0.5 mg (Jalyn) is approved by the US Food and Drug Administration (FDA) in 2010 for treatment of symptomatic BPH in men with an enlarged prostate.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!